Pancreatic Cancer Early Detection Consortium

Recruiting now

Conditions studied: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition

In brief

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Key facts

Study ID: NCT04970056
Run by: Arbor Research Collaborative for Health
People needed: 20000
Starts: 2020-09-18
Expected to finish: 2030-12-31
Last updated by the study team: 2026-07-22

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:
Cohort 1
Individuals without history of PDAC meeting any of the following criteria:
2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
Cohort 2
Individuals without history of PDAC meeting any of the following criteria:
ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
Cohort 6a
Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:
Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
Cohort 6b
Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:
Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11

You may not qualify if…

Individuals not meeting the criteria above.

Where it is running

Honor Health Research Institute — Scottsdale, Arizona, United States (enrolling)
Providence Health and Services — Burbank, California, United States (enrolling)
City of Hope — Duarte, California, United States (enrolling)
UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
UCLA Health — Los Angeles, California, United States (enrolling)
Hoag — Newport Beach, California, United States (enrolling)
UC Irvine Health — Orange, California, United States (enrolling)
UC Davis — Sacramento, California, United States (enrolling)
University of California, San Francisco (UCSF) — San Francisco, California, United States (enrolling)
Yale University — New Haven, Connecticut, United States (enrolling)
Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
University of Miami — Miami, Florida, United States (enrolling)
Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
Emory University Hospital — Atlanta, Georgia, United States (enrolling)
Illinois CancerCare — Bloomington, Illinois, United States (enrolling)
University of Chicago Medicine — Chicago, Illinois, United States (enrolling)
NorthShore University HealthSystem — Evanston, Illinois, United States (enrolling)
University of Kansas Medical Center — Kansas City, Kansas, United States (enrolling)
Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
Umass Memorial Medical Center — Worcester, Massachusetts, United States (enrolling)
University of Michigan — Ann Arbor, Michigan, United States (enrolling)
Beaumont/Corewell Health — Royal Oak, Michigan, United States (enrolling)
University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
Hackensack Meridian Health — Hackensack, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.